Cancer of Head and Neck Clinical Trial
— LIFTINGOfficial title:
Feasibility and Safety of Heavy Lifting Strength Training in Head and Neck Cancer Survivors Post-Surgical Neck Dissection
Verified date | September 2022 |
Source | University of Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The LIFTING trial will examine the feasibility and safety of a heavy lifting strength training (HLST) program in head and neck cancer survivors (HNCS) at least 1 years post surgical neck dissection. The trial will determine whether this training style is safe and feasible in HNCS. Physical and psychosocial changes will also be reported.
Status | Completed |
Enrollment | 9 |
Est. completion date | July 31, 2022 |
Est. primary completion date | July 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - previously diagnosed with any subtype and stage of head and neck cancer - at least one year post surgical neck dissection for head and neck cancer and showing full shoulder range of motion or recovery of the spinal accessory nerve - adults ages 18 and older - no unmanaged medical conditions, alcohol, and drug abuse - approved for a heavy lifting strength training program by the treating surgeon and a certified exercise physiologist - ability to understand and communicate in English Exclusion Criteria: - having comorbidities or uncontrolled medical conditions that their referred clinicians indicate as inappropriate to participate in exercise |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment Rate | Recruitment rate (with reasons for refusal).
Recruitment minimum: 15 participants Recruitment maximum: 20 participants Higher number= better and more data |
Over 12 weeks | |
Primary | Muscular Strength | Change in muscular strength from baseline to postintervention with be assessed using maximal strength tests.
Minimum: none Maximum: none Higher score= better strength |
Changes from baseline to 12 weeks | |
Primary | Program Adherence | Program adherence minimum: 80% Program adherence maximum: 100% Higher score= better adherence | Over 12 weeks | |
Secondary | Physical functioning | Assessed using the Neck Dissection Impairment Index (NDII) and maximum strength tests.
Minimum: 40 Maximum: 100 Higher score= worse impairment |
Changes from baseline to 12 weeks | |
Secondary | Fear of cancer recurrence | Assessed using the Fear of Cancer Recurrence Inventory (FCRI)
Minimum: 0 Maximum: 36 Higher score= worse fear of cancer recurrence |
Changes from baseline to 12 weeks | |
Secondary | Post Traumatic Growth after cancer | How cancer has changed an individual's life will be assessed using the Post Traumatic Growth Inventory (PTGI)
Minimum: 0 Maximum: 105 Higher score= better (positive) post traumatic growth transformation |
Changes from baseline to 12 weeks | |
Secondary | Waist to hip ratio (body composition) | Assessed using waist to hip ratio (WHR) measure.
Minimum WHR: none Maximum WHR: none Higher score WHR= worse body composition |
Changes from baseline to 12 weeks | |
Secondary | Anxiety | Assessed using the Spielberger State Trait Anxiety Inventory (STAI)
Minimum: 20 Maximum: 80 Higher score= worse anxiety |
Changes from baseline to 12 weeks | |
Secondary | Fatigue | Assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire
Minimum: 0 Maximum: 52 Higher score=worse fatigue |
Changes from baseline to 12 weeks | |
Secondary | Stress | Assessed using the Perceived Stress Scale (PSS)
Minimum: 0 Maximum: 56 Higher score=worse perceived stress |
Changes from baseline to 12 weeks | |
Secondary | Shoulder Mobility | Changes in shoulder mobility
Minimum: 150 degrees (18-50 years); 130 degrees (over 50 years) Maximum: none Higher score= better mobility |
Changes from baseline to 12 weeks | |
Secondary | Self-Esteem | Changes in level of self-esteem assessed using Rosenberg Self-Esteem (RSE) scale
Minimum: 10 Maximum: 40 Higher score= better self-esteem |
Changes from baseline to 12 weeks | |
Secondary | Sleep | Changes in sleep patterns assessed using the insomnia severity index (ISI)
Minimum: 0 Maximum: 28 Higher score= worse insomnia |
Changes from baseline to 12 weeks | |
Secondary | Motivation | Questions based on the theory of planned behaviour
Minimum: 7 Maximum: 35 Higher score= better motivation |
Changes from baseline to 12 weeks | |
Secondary | Cancer specific quality of life | Assessed using the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N Symptom Index)
Minimum: 0 Maximum: 40 Higher score= worse head and neck cancer symptoms |
Changes from baseline to 12 weeks | |
Secondary | Cancer Symptom Burden | Assessed using the revised Edmonton Symptom Assessment System (ESAS-r)
Minimum: 0 Maximum: 100 Higher score= worse cancer symptoms |
Changes from baseline to 12 weeks | |
Secondary | Height | Assessed using standing height without shoes.
Minimum height: none Maximum height: none Taller: not specifically better or worse |
Changes from baseline to 12 weeks | |
Secondary | Weight | Assessed using a digital scale without shoes.
Minimum weight: none Maximum weight: none Higher weight: typically worse, but depends on other factors (ie. height, muscle mass, overall health status) |
Changes from baseline to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05331131 -
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial
|
Phase 2 | |
Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
Completed |
NCT03574870 -
Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04804852 -
Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer
|
||
Active, not recruiting |
NCT04617678 -
A Comprehensive Approach to Head and Neck Cancer Prehabilitation
|
N/A | |
Completed |
NCT03419741 -
Brain Stimulation For Cancer Smokers
|
N/A | |
Recruiting |
NCT02528955 -
De-Intensification Radiotherapy Postoperative Head Neck
|
Phase 2 | |
Completed |
NCT00318890 -
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
|
Phase 1/Phase 2 | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Recruiting |
NCT05316974 -
Lymphoedema Among Persons With Head- and Neck Cancer
|
||
Not yet recruiting |
NCT03954691 -
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies
|
||
Active, not recruiting |
NCT03760471 -
Palliative and Oncology Care Intervention: Symptom COACH
|
N/A | |
Completed |
NCT02869399 -
Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention
|
N/A | |
Completed |
NCT02366611 -
Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer
|
N/A | |
Completed |
NCT02075112 -
Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
|
Phase 1 | |
Completed |
NCT00798655 -
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT02900911 -
Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy
|
N/A | |
Completed |
NCT01317589 -
Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
|
Phase 4 | |
Completed |
NCT03841175 -
Forecasts Impact of the Pre-therapeutic TEP-TDM in the 18-FDG Restaging of Upper Aero-digestive Tract Cancers
|
||
Completed |
NCT02865135 -
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
|
Phase 1/Phase 2 |